PON1 and schizophrenia: The second study found reduced serum PON1 activity in patients with schizophrenia treated with olanzapine but not quetiapine, when compared with controls, while serum levels of total cholesterol and LDL-C in the olanzapine group were significantly higher than those of quetiapine and control groups (Ünsal et al. 2013).